4017:TADAWULDr. Soliman Abdul Kader Fakeeh Hospital Co. Analysis

Creema Ltd. is trading at ¥215, just above its 20‑day (¥209.75) and 50‑day (¥207.6) moving averages but still well under the 200‑day SMA (¥235.14), indicating a short‑term bias that is still constrained by longer‑term resistance. The MACD histogram is positive (≈0.93) and the line sits above the signal, signaling bullish momentum, while the RSI at 58 suggests the stock is not yet overbought. Support sits near ¥193 and resistance near ¥233, giving a relatively tight trading range that the price is currently navigating. Fundamentally, the company posts a very high trailing P/E of 52.7 versus a forward P/E of 13.9, implying that earnings are expected to accelerate sharply. Cash on hand (≈¥2.9 bn) dwarfs debt (≈¥0.34 bn), providing a strong balance‑sheet cushion despite modest ROE (≈2.8%). Revenue growth is flat (0.3%) and operating margins are thin (≈1.6%), meaning profitability is still fragile. The stock carries a low dividend yield (0%) and a payout ratio of 0, so income‑focused investors will find little support. Volatility over the past 30 days is around 20 % and beta is low (≈0.22), pointing to modest market‑wide risk but higher price swings. Volume is rising, yet daily trades (~6.8k) remain below the 10‑day average, indicating limited liquidity. Overall, the market’s “Extreme Greed” sentiment (FGI 90.9) is at odds with the company’s modest growth profile, suggesting caution.